TCM Biotech International (TPE:4169) Short-Term Debt: NT$7.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4169 TCM Biotech International Corp TPE:4169
52 GF Score
Price NT$157.00
GF Value NT$42.31
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is TCM Biotech International Short-Term Debt?

TCM Biotech International TPE:4169 -2.48% 52 Short-Term Debt is NT$7.8 Mil as of Mar. 2026. GuruFocus rates TPE:4169 with a GF Score™ of 52/100 and a GF Value™ of NT$42.31 (Significantly Overvalued). The stock has 3 warning signs investors should review.

TCM Biotech International's Short-Term Debt for the quarter that ended in Mar. 2026 was NT$7.8 Mil.

TCM Biotech International's quarterly Short-Term Debt increased from Sep. 2025 (NT$7.2 Mil) to Dec. 2025 (NT$9.2 Mil) but then declined from Dec. 2025 (NT$9.2 Mil) to Mar. 2026 (NT$7.8 Mil).

TCM Biotech International's annual Short-Term Debt declined from Dec. 2023 (NT$57.3 Mil) to Dec. 2024 (NT$10.6 Mil) and declined from Dec. 2024 (NT$10.6 Mil) to Dec. 2025 (NT$9.2 Mil).

TCM Biotech International Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

TCM Biotech International Short-Term Debt Related Terms

TCM Biotech International Short-Term Debt Historical Data

* Premium members only.

The historical data trend for TCM Biotech International's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TCM Biotech International Short-Term Debt Chart

TCM Biotech International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.09 68.12 57.29 10.62 9.17

TCM Biotech International Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 14.34 7.20 9.17 7.77
TPE:4169
52GF Score
TCM Biotech International Corp TPE:4169
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of NT$7.8 Mil mean?
TCM Biotech International (TPE:4169) has a Short-Term Debt of NT$7.8 Mil as of Mar. 2026.
Is TCM Biotech International's Short-Term Debt too high?
TCM Biotech International's current Short-Term Debt is NT$7.8 Mil. Overall, TCM Biotech International has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TCM Biotech International's Short-Term Debt compare to VRTX and REGN?
TCM Biotech International's Short-Term Debt of NT$7.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. TCM Biotech International's current Short-Term Debt is NT$7.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TCM Biotech International stock overvalued right now?
Based on GuruFocus' analysis, TCM Biotech International (TPE:4169) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$42.31, compared to a current price of NT$157.00 — trading 271.1% above its estimated fair value. The current Short-Term Debt is NT$7.8 Mil. TCM Biotech International's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For TCM Biotech International (TPE:4169), the current Short-Term Debt is NT$7.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TCM Biotech International (TPE:4169) Overvalued in 2026?

Based on GuruFocus' analysis, TCM Biotech International stock appears to be overvalued. The current stock price of NT$157.00 is trading 271.1% above its estimated GF Value™ of NT$42.31. GuruFocus considers TCM Biotech International to be Significantly Overvalued.

Key valuation signals for TPE:4169:

  • Short-Term Debt: NT$7.8 Mil
  • GF Value™: NT$42.31 vs. price of NT$157.00 (271.1% above fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the TPE:4169 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TCM Biotech International Business Description

Address No. 97, Section 1, Xintai 5th Road, 24th Floor-8, Xizhi District, Neihu District, Taipei, TWN, 221416
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
52GF Score

Get the complete analysis for TPE:4169

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$157.00
Price
NT$42.31
GF Value